Fosun Pharmaceutical (02196) issued an announcement to satisfy Fosun Kate Biotechnology Co., Ltd. (hereinafter referred to as “Fosun Kate...
Zhitong Finance App News, Fosun Pharmaceutical (02196) announced that in order to meet the business plans and capital requirements of Fosun Kate Biotechnology Co., Ltd. (hereinafter referred to as “Fosun Kate”), it is proposed to request the shareholders' meeting of the company's shareholders' approval for the holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (“Fosun Pharmaceutical Industry”) and Kite Pharma, Inc. (hereinafter referred to as “Kite Pharma”), the other shareholder of Fosun Kate, to renew and add no more than the total equivalent value of Fosun Kate according to their respective shares in Fosun Kate A loan of 67 million US dollars (including principal amount) (including direct loans or entrustment loans, etc., same below). Of these, Fosun Pharmaceutical Industries plans to provide it with a loan of no more than 33.5 million US dollars (including principal amount) according to the shareholding ratio (that is, 50%).